
Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.
Aman Chauhan, MD, is the leader of the Neuroendocrine Tumor Program
and co-director of the Theragnostic Program at the University of Miami Health System.

Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.

Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.

Aman Chauhan, MD, discusses the mechanism and benefits of lutetium oxodotreotide.